Explore this test

  • Test Details
  • Lab Values
  • Clinical Significance
  • Treatment Options
DOWNLOAD SPECIMEN PREP FLYER

Explore this test

Test Code 87300

Test Details

CVMap

Boston Heart Diagnostic’s foundational CVMap provides a comprehensive insight into CVD risk by augmenting standard lipid assessment with advanced diagnostics. The unique combination of biomarkers – lipids and Lp(a) levels, as well as lipid particle numbers; markers of inflammation; and BHD’s unique Cholesterol Balance reporting are informative and actionable.

Methodology

Various methodologies are used. See individual test for more details

Patient Preparation

8 hour fast prior to collection. Patient may drink water only.

Preferred Specimen

Both Serum and Plasma are needed

Alternate Specimen

None

Transport Temperature

Refrigerated (ship on frozen cold packs)

Stability

3 days at 2-8°C.

Lab Values

Lab Values

CVMap

BioMarkerLab Values (view will take you to individual test pages)
Lipids
Total cholesterol View
Direct LDL-CView
sdLDL-C View
HDL-C View
TriglyceridesView
NonHDLView
TC/HDL-C View
HDL-C/TG View
apoBView
Lp(a) View
LDL-PView
HDL-P
Optimal: >44     Borderline: 34-44         Increased Risk: <34 umol/L
Small LDL-P
Optimal: <450   Borderline: 450-950     Increased Risk: >950 umol/L 
Large HDL-P
Optimal: >11.1  Borderline: 4.8-11.1      Increased Risk: <4.8 umol/L
Large VLDL-P
Optimal: <2.0    Borderline: 2.0-4.7        Increased Risk: >4.7 umol/L
Cholesterol Balance
Production MarkersView
Absorption MarkersView
Inflammation
hs-CRPView
LpPLA2View
Test Details
Clinical Significance

Clinical Significance

CVMap

BioMarkerBioMarker Description
Lipids
Total cholesterol Amount of cholesterol in all cholesterol-containing lipoproteins.
Direct LDL-CDirect measurement of the amount of cholesterol in atherogenic low-density lipoproteins.
sdLDL-C Amount of cholesterol in the densest and most atherogenic LDL particles. Stronger predictor of cardiovascular disease (CVD) than apoB or LDL-P.
HDL-C Amount of cholesterol in high-density lipoproteins (HDL). Higher levels of HDL are associated with reduced CVD; however, very high concentrations have shown increased risk for adverse outcomes in certain populations.
TriglyceridesElevated levels increase CVD risk by altering lipoprotein metabolism.
NonHDLCalculation that represents the cholesterol carried by all atherogenic particles. It is an independent risk factor for ASCVD, especially in patients on statin therapy and/or with obesity, diabetes, and metabolic disorders.
TC/HDL-C Lipid ratio that is a stronger risk factor than LDL-C or HDL-C.
HDL-C/TG Lipid ratio associated with insulin resistance.
apoBMajor protein component of LDL-C and other atherogenic lipoproteins.
Lp(a) Lipoprotein particle similar to LDL-C that contains an additional protein called apolipoprotein(a). Independent, predominantly genetically determined, and prevalent causal risk factor for atherosclerotic heart disease.
LDL-PTotal number of LDL particles in blood. High levels of LDL-P are a strong, independent predictor of CVD.
HDL-PTotal number of HDL particles in blood. Lower concentration of HDL particles has been independently associated with coronary artery disease (CAD) risk.
Small LDL-PTotal number of small low-density lipoprotein articles in blood. A higher level of small LDL-P has been seen to be elevated in individuals with Metabolic Syndrome.
Large HDL-PAmount of large high-density lipoprotein particles in blood. Studies suggest a strong association between HDL-P size and risk factors characteristic of the metabolic syndrome.
Large VLDL-PAmount of large low-density lipoprotein particles in blood.
Cholesterol Balance
Production MarkersElevated lathosterol and desmosterol indicate cholesterol over-production and can be treated with agents that reduce production.
Absorption MarkersElevated beta-sitosterol or campesterol indicate cholesterol over-absorption and can be treated with agents that reduce absorption.
Inflammation
hs-CRPAcute phase inflammatory protein associated with atherosclerosis (after other causes excluded).
LpPLA2Enzyme produced by monocytes/macrophages that reflects an active inflammatory process in the vessel wall.
Lab Values
Treatment Options

Treatment Options

CVMap

10 Steps in CVD Prevention and Treatment

  • Ensure a diet low saturated and trans fats, rich in essential fatty acids including omega-3s, high in low glycemic fruits and high in vegetable fiber.
  • Include exercise greater than 150 min/week.
  • Smoking cessation.
  • Obtain blood pressure goals of less than 130/90 mmHg.
  • Lower HbA1c to less than 7.0%.
  • Optimize LDL-C to less than 70 mg/dL and sdLDL-C less than 25 mg/dL.
  • Optimize hs-CRP to less than 1.0 mg/L.
  • Optimize Triglycerides with a goal of less than 100 mg/dL and encourage healthy large HDL particles with diet, exercise and fish oil.
  • Manage Homocysteine to a goal of less than 10 µmol/L by using methlyated B vitamins and folate.
  • Manage risk factors associate with Lp(a)elevations.
Clinical Significance